Therapeutic Focus

Schizophrenia patients (ongoing antipsychotic treatment inadequate due to insufficient efficacy and/or tolerability)

A global medical research study is being conducted to document the clinical benefit of Quetiapine Sustained Release (SR) taken once daily after switching from other ongoing antipsychotic treatment, regardless of the reason for the switch.

Benefit to your patient:

  • A 12 week treatment period of treatment with a flexible dose of Quetiapine SR.
  • As part of the study, Seroquel® IR is available for 6 months after the treatment period for patients doing well.

Please contact one of the following investigators for more information:

  • Prof. FY Jeenah (Chris Hani Baragwanath Hospital, Soweto) +27 11 933 9239
  • Dr. MYH Moosa (Chris Hani Baragwanath Hospital, Soweto) +27 11 488 3846
  • Dr. V Agambaram (Entabeni Hospital, Durban) +27 31 261 9120
  • Dr. FA Randeree (Musgrave Park, Durban) +27 31 201 1531
  • Dr. M Slabber (Dey Clinic, Pretoria) +27 12 460 3502
Become a Member